Decision means that health care providers in some states will be able to prescribe mifepristone via telemedicine and mail the pills to patients
TUESDAY, April 13, 2021 (HealthDay News) — A requirement that mifepristone abortion pills be dispensed only in person by a medical provider will be put on hold during the COVID-19 pandemic, the U.S. Food and Drug Administration says.
The decision means that health care providers in some states will be able to prescribe mifepristone via telemedicine and mail the pills to patients, CBS News reported.
The American College of Obstetricians and Gynecologists (ACOG) has said the in-person requirement is medically unnecessary and puts patients and medical staff at risk during the pandemic.
In a letter to ACOG, acting FDA Commissioner Janet Woodcock, M.D., cited four medical publications and wrote, “these studies do not appear to show increases in serious safety concerns…occurring with medical abortion as a result of modifying the in-person dispensing requirement during the COVID-19 pandemic,” CBS News reported.
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus 
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
